| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Departments of Medical Genetics [M. K., R. L., R. S., K. A., S. K., V. L., A. K., L. A. A.] and Pathology [J. A., R. S.], Biomedicum Helsinki or Haartman Institute, University of Helsinki, FIN-00014 Helsinki, Finland; Departments of Surgery [H. J.] and Obstetrics and Gynecology [J. S.], Helsinki University Central Hospital, FIN-00290 Helsinki, Finland; Institute of Medical Technology, University of Tampere and Tampere University Hospital, FIN-33014 Tampere, Finland [T. V., J. I.]; Department of Pathology, University of Otago, Wellington, New Zealand [B. D.]; and Department of Pathology, Oulu University Hospital, FIN-90220 Oulu, Finland [R. H.]
Loss of function mutations in the fumarate hydratase (fumarase, FH) gene were recently identified as the cause for dominantly inherited uterine and cutaneous leiomyomas and renal cell cancer. To further evaluate the role of FH in tumorigenesis, we screened FH mutations from tumor types seen in hereditary leiomyomatosis and renal cell cancer mutation carriers41 uterine and 10 cutaneous leiomyomas, 52 renal cell carcinomas, 53 sarcomas, 29 prostate carcinomas, and 15 lobular breast carcinomas. Few mutations were detected. Biallelic inactivation of FH was found in one uterine leiomyosarcoma, one cutaneous leiomyoma, and one soft tissue sarcoma. Whereas the two former lesions were shown to originate from a germ-line mutation, the soft tissue sarcoma is to our knowledge the first example of purely somatic inactivation of FH in tumors.
This article has been cited by other articles:
![]() |
J. C. Hodge and C. C. Morton Genetic heterogeneity among uterine leiomyomata: insights into malignant progression Hum. Mol. Genet., April 15, 2007; 16(R1): R7 - R13. [Abstract] [Full Text] [PDF] |
||||
![]() |
H J Lehtonen, M Kiuru, S K Ylisaukko-oja, R Salovaara, R Herva, P A Koivisto, O Vierimaa, K Aittomaki, E Pukkala, V Launonen, et al. Increased risk of cancer in patients with fumarate hydratase germline mutation J. Med. Genet., June 1, 2006; 43(6): 523 - 526. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Vanharanta, P. J. Pollard, H. J. Lehtonen, P. Laiho, J. Sjoberg, A. Leminen, K. Aittomaki, J. Arola, M. Kruhoffer, T. F. Orntoft, et al. Distinct expression profile in fumarate-hydratase-deficient uterine fibroids Hum. Mol. Genet., January 1, 2006; 15(1): 97 - 103. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.J. Pollard, J.J. Briere, N.A. Alam, J. Barwell, E. Barclay, N.C. Wortham, T. Hunt, M. Mitchell, S. Olpin, S.J. Moat, et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1{alpha} in tumours which result from germline FH and SDH mutations Hum. Mol. Genet., August 1, 2005; 14(15): 2231 - 2239. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Matyakhina, R. J. Freedman, I. Bourdeau, M.-H. Wei, S. G. Stergiopoulos, A. Chidakel, M. Walther, M. Abu-Asab, M. Tsokos, M. Keil, et al. Hereditary Leiomyomatosis Associated with Bilateral, Massive, Macronodular Adrenocortical Disease and Atypical Cushing Syndrome: A Clinical and Molecular Genetic Investigation J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3773 - 3779. [Abstract] [Full Text] [PDF] |
||||
![]() |
M R Morris, E Maina, N V Morgan, D Gentle, D Astuti, H Moch, T Kishida, M Yao, P Schraml, F M Richards, et al. Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma J. Clin. Pathol., July 1, 2004; 57(7): 706 - 711. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Dulaimi, I. I. de Caceres, R. G. Uzzo, T. Al-Saleem, R. E. Greenberg, T. J. Polascik, J. S. Babb, W. E. Grizzle, and P. Cairns Promoter Hypermethylation Profile of Kidney Cancer Clin. Cancer Res., June 15, 2004; 10(12): 3972 - 3979. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Lehtonen, M. Kiuru, S. Vanharanta, J. Sjoberg, L.-M. Aaltonen, K. Aittomaki, J. Arola, R. Butzow, C. Eng, K. Husgafvel-Pursiainen, et al. Biallelic Inactivation of Fumarate Hydratase (FH) Occurs in Nonsyndromic Uterine Leiomyomas but Is Rare in Other Tumors Am. J. Pathol., January 1, 2004; 164(1): 17 - 22. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Khoo, K. Kahnoski, J. Sugimura, D. Petillo, J. Chen, K. Shockley, J. Ludlow, R. Knapp, S. Giraud, S. Richard, et al. Inactivation of BHD in Sporadic Renal Tumors Cancer Res., August 1, 2003; 63(15): 4583 - 4587. [Abstract] [Full Text] [PDF] |
||||
![]() |
P Laiho, T Hienonen, J-P Mecklin, H Jarvinen, A Karhu, V Launonen, and L A Aaltonen Mutation and LOH analysis of ACO2 in colorectal cancer: no evidence of biallelic genetic inactivation J. Med. Genet., May 1, 2003; 40(5): e73 - 73. [Full Text] [PDF] |
||||
![]() |
S.-Y. Lee, Y. Obata, M. Yoshida, E. Stockert, B. Williamson, A. A. Jungbluth, Y.-T. Chen, L. J. Old, and M. J. Scanlan Immunomic analysis of human sarcoma PNAS, March 4, 2003; 100(5): 2651 - 2656. [Abstract] [Full Text] [PDF] |
||||
![]() |
R Lehtonen, M Kiuru, A Rokman, T Ikonen, J M Cunningham, D J Schaid, M Matikainen, N N Nupponen, A Karhu, O-P Kallioniemi, et al. No fumarate hydratase (FH) mutations in hereditary prostate cancer J. Med. Genet., March 1, 2003; 40(3): e19 - 19. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |